Verrica Pharmaceuticals Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Verrica Pharmaceuticals Inc. filed its Q1 2024 10-Q, detailing financial activities and agreements.</b>

AI Summary

Verrica Pharmaceuticals Inc. (VRCA) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Verrica Pharmaceuticals Inc. filed a 10-Q report for the period ending March 31, 2024. The filing includes data related to various financial instruments and agreements, such as Term A Loans and Senior Loan Agreements. Key dates mentioned include July 26, 2023, for loan facility availability and February 28, 2023, for underwritten offerings and pre-funded warrants. The company's fiscal year ends on December 31. Verrica Pharmaceuticals Inc. is categorized under Pharmaceutical Preparations (SIC 2834).

Why It Matters

For investors and stakeholders tracking Verrica Pharmaceuticals Inc., this filing contains several important signals. This 10-Q filing provides an update on Verrica's financial position and operational activities for the first quarter of 2024, which is crucial for investors to assess the company's performance and outlook. The details on loan facilities and equity transactions offer insights into the company's capital structure and funding strategies.

Risk Assessment

Risk Level: medium — Verrica Pharmaceuticals Inc. shows moderate risk based on this filing. The filing is a standard quarterly report (10-Q) and does not contain immediate, significant negative news, but the absence of specific financial performance data in the provided snippet necessitates a neutral-to-medium risk assessment.

Analyst Insight

Investors should review the full 10-Q filing to understand Verrica Pharmaceuticals' financial performance, debt obligations, and any forward-looking statements.

Key Numbers

• 2024-03-31 — Reporting Period End Date (10-Q filing)
• 2024-05-13 — Filing Date (10-Q filing)
• 2023-07-26 — Loan Facility Availability Date (Senior Loan Agreement, Term A Loan)
• 2023-02-28 — Underwritten Offering and Warrant Date (Pre-funded warrant)

Key Players & Entities

• Verrica Pharmaceuticals Inc. (company) — Filer of the 10-Q report
• 2024-03-31 (date) — Conformed period of report
• 2024-05-13 (date) — Filed as of date
• 10-Q (form) — Type of filing
• 2834 (sic_code) — Standard Industrial Classification for Pharmaceutical Preparations
• 19380 (zip_code) — Business address zip code
• 484-453-3300 (phone_number) — Business phone number
• Lytix Biopharma AS (company) — Mentioned in relation to dates

FAQ

Risk Factors

• Financial Condition [medium — financial]: The 10-Q filing provides details on the company's financial condition as of March 31, 2024, including information on debt facilities and equity transactions.

Key Dates

• 2024-03-31: Quarterly Period End — End of the reporting period for the 10-Q
• 2024-05-13: Filing Date — Date the 10-Q was officially filed with the SEC
• 2023-07-26: Loan Facility Agreement Date — Date related to the availability of Term A Loan and Senior Loan Agreement
• 2023-02-28: Equity Offering Date — Date related to Underwritten Offering and Pre-funded Warrant

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value VRCA The Nasdaq Stock Mar

Filing Documents

• vrca-20240331.htm (10-Q) — 1165KB
• vrca-ex31_1.htm (EX-31.1) — 13KB
• vrca-ex31_2.htm (EX-31.2) — 13KB
• vrca-ex32_1.htm (EX-32.1) — 11KB
• 0000950170-24-058208.txt (&nbsp;) — 5868KB
• vrca-20240331.xsd (EX-101.SCH) — 1153KB
• vrca-20240331_htm.xml (XML) — 813KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 14 Item 3.

Quantitative and Qualitative Disclosures About Market Risks

Quantitative and Qualitative Disclosures About Market Risks 21 Item 4.

Controls and Procedures

Controls and Procedures 21

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 22 Item 1A.

Risk Factors

Risk Factors 22 Item 5. Other Information 22 Item 6. Exhibits 22

FINANC IAL INFORMATION

PART I. FINANC IAL INFORMATION

Unaudited Financial Statements

Item 1. Unaudited Financial Statements VERRICA PHARMACEUTICALS INC. BA LANCE SHEETS (in thousands, except share and per share amounts) (unaudited) March 31, December 31, 2024 2023 ASSETS Current assets: Cash and cash equivalents $ 48,939 $ 69,547 Accounts receivable 7,002 4,248 Unbilled collaboration revenue 592 168 Inventory 2,499 1,022 Prepaid expenses and other current assets 2,344 2,545 Total current assets 61,376 77,530 Property and equipment, net 937 1,052 Operating lease right-of-use asset 1,082 1,158 Finance lease right-of-use asset 2,460 1,405 Other non-current assets 452 452 Total assets $ 66,307 $ 81,597 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 2,527 $ 2,464 Accrued expenses and other current liabilities 15,828 13,860 Operating lease liability 331 324 Finance lease liability 679 376 Total current liabilities 19,365 17,024 Operating lease liability 825 910 Finance lease liability 1,761 1,026 Long term debt 42,848 42,874 Total liabilities 64,799 61,834 Commitments and Contingencies (Note 6) Stockholders' equity: Preferred stock, $ 0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2024 and December 31, 2023 — — Common stock, $ 0.0001 par value; 200,000,000 authorized; 42,525,197 shares issued and 42,420,053 shares outstanding as of March 31, 2024 and 42,518,697 shares issued and 42,413,553 shares outstanding as of December 31, 2023 4 4 Treasury stock, at cost, 105,144 shares as of March 31, 2024 and December 31, 2023 — — Additional paid-in capital 252,287 250,207 Subscription receivable ( 4 ) — Accumulated deficit ( 250,779 ) ( 230,448 ) Total stockholders' equity 1,508 19,763 Total liabilities and stockholders' equity $ 66,307 $ 81,597 The accompanying notes

Notes to Financial Statements

Notes to Financial Statements (Unaudited) Note 1— Organization and Description of Business Operations Verrica Pharmaceuticals Inc. (the "Company") was formed on July 3, 2013 and is incorporated in the State of Delaware. The Company is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. On July 21, 2023, the U.S. Food and Drug Administration ("FDA") approved YCANTH (VP-102) topical solution for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. The Company launched commercial operations in August 2023. Liquidity The Company has incurred substantial operating losses since inception and expects to continue to incur significant losses for the foreseeable future and may never become profitable. As of March 31, 2024, the Company had an accumulated deficit of $ 250.8 million. The Company believes its cash, and cash equivalents of $ 48.9 million as of March 31, 2024 will be sufficient to support the Company's planned operations only into the first quarter of 2025. These factors cause substantial doubt to exist about the Company's ability to continue as a going concern within one year after the date these financial statements are issued. The Company's financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result should the Company be unable to continue as a going concern. The Company plans to secure additional capital in the future through equity or debt financings, partnerships, or other sources to carry out the Company's planned commercial and development activities. If the Company is unable to raise capital w

View Full Filing

View this 10-Q filing on SEC EDGAR